JP2007529492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529492A5 JP2007529492A5 JP2007503413A JP2007503413A JP2007529492A5 JP 2007529492 A5 JP2007529492 A5 JP 2007529492A5 JP 2007503413 A JP2007503413 A JP 2007503413A JP 2007503413 A JP2007503413 A JP 2007503413A JP 2007529492 A5 JP2007529492 A5 JP 2007529492A5
- Authority
- JP
- Japan
- Prior art keywords
- condition
- composition
- pain
- disease
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 17
- 208000002193 Pain Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000018035 Dental disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000014151 Stomatognathic disease Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- RFIXURDMUINBMD-UHFFFAOYSA-N bufeniode Chemical compound C=1C(I)=C(O)C(I)=CC=1C(O)C(C)NC(C)CCC1=CC=CC=C1 RFIXURDMUINBMD-UHFFFAOYSA-N 0.000 claims 1
- 229950003250 bufeniode Drugs 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- VHSBBVZJABQOSG-MRXNPFEDSA-N denopamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC[C@@H](O)C1=CC=C(O)C=C1 VHSBBVZJABQOSG-MRXNPFEDSA-N 0.000 claims 1
- 229950007304 denopamine Drugs 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229960003998 ifenprodil Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229960004819 isoxsuprine Drugs 0.000 claims 1
- 229960001632 labetalol Drugs 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- MPQWSYJGFLADEW-UHFFFAOYSA-N medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 claims 1
- 229950008578 medroxalol Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- -1 neuroleptics Substances 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical compound C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 claims 1
- 229940074095 ractopamine Drugs 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 claims 1
- 229960001634 ritodrine Drugs 0.000 claims 1
- 229950001879 salmefamol Drugs 0.000 claims 1
- PAQZZCOZHPGCFW-UHFFFAOYSA-N sulfinalol Chemical compound C1=CC(OC)=CC=C1CCC(C)NCC(O)C1=CC=C(O)C(S(C)=O)=C1 PAQZZCOZHPGCFW-UHFFFAOYSA-N 0.000 claims 1
- 229950005165 sulfinalol Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0406016A GB0406016D0 (en) | 2004-03-17 | 2004-03-17 | The treatment of inflammatory disorders |
| GB0418556A GB0418556D0 (en) | 2004-08-19 | 2004-08-19 | The treatment of pain |
| GB0422880A GB0422880D0 (en) | 2004-10-14 | 2004-10-14 | The treatment of inflammatory disorders |
| PCT/GB2005/001031 WO2005089741A2 (en) | 2004-03-17 | 2005-03-17 | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007529492A JP2007529492A (ja) | 2007-10-25 |
| JP2007529492A5 true JP2007529492A5 (https=) | 2008-05-01 |
Family
ID=34962997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503413A Withdrawn JP2007529492A (ja) | 2004-03-17 | 2005-03-17 | β−アミノアルコール類を用いる炎症性障害及び疼痛の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070179181A1 (https=) |
| EP (1) | EP1725226A2 (https=) |
| JP (1) | JP2007529492A (https=) |
| AU (1) | AU2005224160A1 (https=) |
| CA (1) | CA2558126A1 (https=) |
| WO (1) | WO2005089741A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589001A1 (en) * | 2004-11-19 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for neuropathic pain |
| CN101203214B (zh) * | 2005-04-13 | 2012-11-21 | 艾升制药公司 | 用于治疗皮肤结缔组织疾病的β2-肾上腺素受体激动剂 |
| GB0519274D0 (en) * | 2005-09-21 | 2005-11-02 | Arakis Ltd | The treatment of neurodegenerative diseases |
| GB0523964D0 (en) * | 2005-11-24 | 2006-01-04 | Arakis Ltd | The treatment of ophthalmic diseases |
| GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
| FR2926464B1 (fr) * | 2008-01-18 | 2012-01-20 | Centre Nat Rech Scient | Composes utilisables pour le traitement de douleurs neuropathiques |
| WO2009112674A2 (fr) * | 2008-01-18 | 2009-09-17 | Centre National De La Recherche Scientifique - Cnrs | Composes utilisables pour le traitement de douleurs neuropathiques |
| US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
| EP2544677A4 (en) * | 2010-03-08 | 2013-07-10 | Univ Tennessee Res Foundation | BETA-ADRENERGE RECEPTOR AGONISTS AND USES THEREOF |
| GB2484977A (en) * | 2010-10-29 | 2012-05-02 | Biocopea Ltd | Treatment of a Th-1 mediated disease |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| CN104807909A (zh) * | 2015-05-12 | 2015-07-29 | 广西壮族自治区梧州食品药品检验所 | 高精度测量猪尿中的克仑特罗含量的方法 |
| CN104820047B (zh) * | 2015-05-12 | 2016-06-29 | 广西壮族自治区梧州食品药品检验所 | 采用sle法同时分离猪尿中的莱克多巴胺、克仑特罗、沙丁胺醇的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6087M (https=) * | 1967-01-10 | 1968-06-04 | ||
| US4086363A (en) * | 1977-03-16 | 1978-04-25 | Usv Pharmaceutical Corporation | Treatment of asthma |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US6043283A (en) * | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
| GB9804886D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
| GB9804885D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
| AU2001225664A1 (en) * | 2000-06-15 | 2001-12-24 | Respiratorius Ab | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
| AU2002212888A1 (en) * | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
| WO2002036114A1 (en) * | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
| EP1370240A4 (en) * | 2001-03-02 | 2004-09-22 | Neuron Therapeutics Inc | NEUROPROTECTOR FORMULATIONS AND METHOD |
| EP1496917B1 (en) * | 2002-04-19 | 2005-12-07 | Astion Development A/S | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| AU2003228819A1 (en) * | 2002-05-03 | 2003-11-17 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory skin disorders |
| GB0210264D0 (en) * | 2002-05-03 | 2002-06-12 | Arakis Ltd | The treatment of pain and migraine headache |
| US20040209850A1 (en) * | 2003-04-15 | 2004-10-21 | Theraquest Biosciences, Llc | Methods of treating pain and compositions for use therefor |
| ES2284025T3 (es) * | 2003-07-29 | 2007-11-01 | Boehringer Ingelheim International Gmbh | Medicamentos para inhalar que comprenden betamimeticos y un anticolinergico. |
| US7462618B2 (en) * | 2003-08-27 | 2008-12-09 | Sun Health Research Institute | Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists |
| EP1677778A2 (en) * | 2003-10-09 | 2006-07-12 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| AU2004285329A1 (en) * | 2003-10-21 | 2005-05-12 | Arakis Ltd. | The use of ifenprodil in the treatment of pain |
-
2005
- 2005-03-17 CA CA002558126A patent/CA2558126A1/en not_active Abandoned
- 2005-03-17 WO PCT/GB2005/001031 patent/WO2005089741A2/en not_active Ceased
- 2005-03-17 EP EP05718072A patent/EP1725226A2/en not_active Withdrawn
- 2005-03-17 AU AU2005224160A patent/AU2005224160A1/en not_active Abandoned
- 2005-03-17 JP JP2007503413A patent/JP2007529492A/ja not_active Withdrawn
- 2005-03-17 US US10/591,137 patent/US20070179181A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529492A5 (https=) | ||
| JP2004534816A5 (https=) | ||
| JP2023508469A5 (https=) | ||
| JP2012502111A5 (https=) | ||
| JP2012504133A5 (https=) | ||
| JP2007508361A5 (https=) | ||
| NZ602496A (en) | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | |
| JP2002536359A5 (https=) | ||
| JP2020528431A5 (https=) | ||
| JP2012523440A5 (https=) | ||
| CL2007003502A1 (es) | Compuestos derivados de pirimidin-amina, moduladores de jnk; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento de artritis reumatoide, asma, diabetes tipo ii, enfermedad de alzheimer, enfermedad de parkinson y apoplejia. | |
| JP2013542261A5 (https=) | ||
| JP2013523623A5 (https=) | ||
| JP2011530521A5 (https=) | ||
| JP2008543860A5 (https=) | ||
| TW200745135A (en) | Therapeutic agents | |
| MX2010002576A (es) | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. | |
| IL195409A0 (en) | 1,3-disubstituted 4-methyl-1h-pyrrole-2-carboxamides and their use for the manufacture of medicaments | |
| JP2015502371A5 (https=) | ||
| JP2013525490A5 (https=) | ||
| JP2007515467A5 (https=) | ||
| JP2008508248A5 (https=) | ||
| JP2010517991A5 (https=) | ||
| JP2006503816A5 (https=) | ||
| WO2005089741A3 (en) | The treatment of inflammatory disorders and pain using beta-aminoalcohols |